TY - JOUR T1 - Measuring health in pulmonary hypertension: emphasising the right end-point? JF - European Respiratory Journal JO - Eur Respir J SP - 960 LP - 962 DO - 10.1183/09031936.00001014 VL - 43 IS - 4 AU - Mardi Gomberg-Maitland AU - Hubert Chen Y1 - 2014/04/01 UR - http://erj.ersjournals.com/content/43/4/960.abstract N2 - Pulmonary hypertension (PH) is a condition deriving from multiple aetiologies with the recent focus on Group 1 pulmonary arterial hypertension (PAH) and Group 4 chronic thromboembolic pulmonary hypertension (CTEPH) largely due to the surge of understanding in pathophysiology and resultant treatments available [1]. Both are a disease of the pulmonary circulation that is characterised by a progressive rise in pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR), with limited dysfunction of the left ventricle [2]. Symptoms manifest as patients’ lose the ability to augment their cardiac output in the face of a fixed vascular resistance [3]. In addition, anxiety and depression disorders are highly prevalent in PAH and CTEPH patients and correlate with the patients’ sense of wellness [4]. However, despite therapeutic options and overall improved outcomes, life expectancy is shortened [5, 6] and patients must face the myriad of issues that go along with a chronic debilitating fatal disease [7–9].The definition of “good health” is not just the absence of disease but also incorporates emotional and physical security, a sense of contentment. The World Health Organization first formally acknowledged this concept in the 1952 … ER -